With big Keytruda and Opdivo data coming at AACR, analyst hands Merck the early edge

With both Merck and Bristol-Myers Squibb rolling out closely watched data on their immuno-oncology contenders at a medical meeting this weekend, one thing’s for sure: Investors will be drawing comparisons.